

## **CBD Novel Food Guidance**

1. Cannabidiol (CBD) consumables marketed as food supplements necessitate a Novel Food (NF) authorisation for sale in the Great Britain (GB) market. Specifically, your CBD products need to be covered by a Novel Food application that has been lodged with the Food Standards Agency (FSA), or they must have their own independent NF application.
2. At present, novel food authorisation pertains solely to CBD consumables. However, all cannabinoids (including CBG, CBC, etc.) are deemed novel and are thus not permitted for sale in the GB or EU market. Other cannabinoids are not presently eligible for listing publicly due to temporary measures for CBD products that exclude them from the scope.
3. As partners of the EIHA consortium, we're actively involved with two applications submitted to the FSA for CBD Isolates and Full Spectrum CBD (Distillates). These applications have been validated and are awaiting final approval. EIHA's Novel Food application numbers are RP427 for CBD Isolate and RP438 for Full Spectrum CBD.
4. Partners of EIHA projects GmbH wholly own the rights to EIHA's toxicology studies and scientific data. These ensure the safety of the products we supply to our clients. Hence, we guarantee that all whitelabel products we manufacture and distribute contain FSA compliant ingredients and are appropriately labelled for the GB market.
5. The FSA mandates that every CBD food product and brand needs novel food authorisation to be launched on the GB market. This includes all CBD food products, even White Label product variations, irrespective of whether the same product is authorised under another brand.
6. The FSA is still accepting Novel Food Applications for CBD. However, these Novel Food Applications fall into the category of 'new products' and hence cannot be marketed until the supporting application has been 'authorised'. A 'validated' application does not in itself enable new products to be introduced into the UK market. The FSA required CBD applications to be submitted before 31st March 2021, for businesses to continue to sell existing CBD products. All CBD applications submitted after this date would need authorisation before the products linked to them are permitted on the GB market.
7. Brand owners bear the responsibility of ensuring their products have received novel food authorisation before introducing them into the GB market.
8. If you have not already submitted an application for your products, we can sublicense these under EIHA's application only once they receive authorisation from the FSA.
9. Novel Food sublicensing can be obtained for a fee set by EIHA, which currently begins at 2,156.25 EUR (and is subject to biannual increases). For more information about the sublicensing process, contact us at [whitelabel@jm-wholesale.co.uk](mailto:whitelabel@jm-wholesale.co.uk).
10. For further details, please refer to the FSA's CBD Novel food guidelines at <https://www.food.gov.uk/business-guidance/cbd-products-linked-to-novel-food-applications>.

This statement aims to inform customers about compliance requirements and our role as a manufacturer. We encourage you to familiarize yourself with these guidelines to ensure your products comply with these regulations. For the most current information, we kindly advise you to get in touch with the FSA.